These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17372715)

  • 21. Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells.
    Wu AJ; Park II; Zhaung L; Lee C
    Prostate; 2002 Dec; 53(4):277-85. PubMed ID: 12430139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat shock proteins: endogenous modulators of apoptotic cell death.
    Garrido C; Gurbuxani S; Ravagnan L; Kroemer G
    Biochem Biophys Res Commun; 2001 Aug; 286(3):433-42. PubMed ID: 11511077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Heat shock proteins: new target in cytoprotective and tumor therapy].
    Bao XQ; Liu GT
    Yao Xue Xue Bao; 2008 Mar; 43(3):234-40. PubMed ID: 18630257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting heat shock proteins in metastatic castration-resistant prostate cancer.
    Azad AA; Zoubeidi A; Gleave ME; Chi KN
    Nat Rev Urol; 2015 Jan; 12(1):26-36. PubMed ID: 25512207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H; Nelson C; Rennie PS; Gleave ME
    Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress.
    Viard I; Wehrli P; Jornot L; Bullani R; Vechietti JL; Schifferli JA; Tschopp J; French LE
    J Invest Dermatol; 1999 Mar; 112(3):290-6. PubMed ID: 10084304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clusterin inhibits apoptosis by interacting with activated Bax.
    Zhang H; Kim JK; Edwards CA; Xu Z; Taichman R; Wang CY
    Nat Cell Biol; 2005 Sep; 7(9):909-15. PubMed ID: 16113678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells.
    Ren A; Yan G; You B; Sun J
    Cancer Res; 2008 Apr; 68(7):2266-74. PubMed ID: 18381433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.
    Zoubeidi A; Zardan A; Beraldi E; Fazli L; Sowery R; Rennie P; Nelson C; Gleave M
    Cancer Res; 2007 Nov; 67(21):10455-65. PubMed ID: 17974989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New molecular targets in advanced prostate cancer.
    Dawson NA
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
    Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
    Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
    Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
    Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
    Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
    Gray PJ; Stevenson MA; Calderwood SK
    Cancer Res; 2007 Dec; 67(24):11942-50. PubMed ID: 18089825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular chaperones: toward new therapeutic tools.
    Almeida MB; do Nascimento JL; Herculano AM; Crespo-López ME
    Biomed Pharmacother; 2011 Jul; 65(4):239-43. PubMed ID: 21737228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy.
    Wang XZ; Beebe JR; Pwiti L; Bielawska A; Smyth MJ
    Cancer Res; 1999 Nov; 59(22):5842-8. PubMed ID: 10582708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer: status of current treatments and emerging antisense-based therapies.
    Devi GR
    Curr Opin Mol Ther; 2002 Apr; 4(2):138-48. PubMed ID: 12044035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.